WWP2 Is One Promising Novel Oncogene

Rui Zhang1, Jianwu Zhang2, Wei Luo3

  • 1Department of Thoracic Surgery, The Seventh People's Hospital of Chengdu, Chengdu, Sichuan, 640021, People's Republic of China.

Insights

WWP2, an E3 ubiquitin ligase, is a novel oncogene driving tumor development via the PTEN/Akt pathway. It also influences cancer treatment sensitivity, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • WWP2 functions as an E3 ubiquitin ligase, regulating cellular processes via substrate ubiquitination and degradation.
  • Emerging evidence highlights WWP2's significant role in the pathogenesis of various tumors.

Purpose of the Study:

  • To review the role of WWP2 in tumorigenesis.
  • To explore WWP2's involvement in cancer development and its potential as a therapeutic target.

Main Methods:

  • Literature review of studies on WWP2 and cancer.
  • Analysis of WWP2's role in cancer pathogenesis and signaling pathways.
  • Investigation of WWP2's impact on anti-cancer agent sensitivity.

Main Results:

  • WWP2 is dysregulated across numerous tumor types.
  • WWP2 promotes carcinogenesis, primarily through the PTEN/Akt signaling pathway.
  • WWP2 influences the efficacy of anti-cancer treatments.

Conclusions:

  • WWP2 is implicated as a novel oncogene in cancer development.
  • Targeting WWP2 may represent a promising strategy for cancer therapy.